EA202090221A1 - USE OF EDARAVON FOR ORAL TREATMENT OF MEDIATED OXIDATIVE STRESS OF NEURODEGENERATIVE DISORDERS - Google Patents

USE OF EDARAVON FOR ORAL TREATMENT OF MEDIATED OXIDATIVE STRESS OF NEURODEGENERATIVE DISORDERS

Info

Publication number
EA202090221A1
EA202090221A1 EA202090221A EA202090221A EA202090221A1 EA 202090221 A1 EA202090221 A1 EA 202090221A1 EA 202090221 A EA202090221 A EA 202090221A EA 202090221 A EA202090221 A EA 202090221A EA 202090221 A1 EA202090221 A1 EA 202090221A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxidative stress
edaravone
neurodegenerative disorders
edaravon
treatment
Prior art date
Application number
EA202090221A
Other languages
Russian (ru)
Inventor
Роналд Ван Дер Гест
Ситске Хике Моленар
Original Assignee
Триуэй Тв001 Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Триуэй Тв001 Б.В. filed Critical Триуэй Тв001 Б.В.
Priority claimed from PCT/EP2018/068396 external-priority patent/WO2019008144A1/en
Publication of EA202090221A1 publication Critical patent/EA202090221A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к применению жидкого водного раствора эдаравона для лечения опосредуемого окислительным стрессом нейродегенеративного нарушения у пациента-человека, причем указанное лечение включает пероральное введение по меньшей мере один раз в сутки жидкого раствора эдаравона пациенту-человеку для обеспечения суточной дозы 40-120 мг эдаравона в ходе непрерываемого периода по меньшей мере 10 суток. Примеры опосредуемых окислительным стрессом нейродегенеративных нарушений, которые можно лечить таким образом, включают боковой амиотрофический склероз (ALS), рассеянный склероз (MS), церебральную амилоидную ангиопатию (CAA), болезнь Альцгеймера и болезнь Паркинсона.The present invention relates to the use of a liquid aqueous edaravone solution for the treatment of oxidative stress mediated neurodegenerative disorder in a human patient, said treatment comprising administering at least once daily oral edaravone liquid solution to a human patient to provide a daily dose of 40-120 mg of edaravone b during an uninterrupted period of at least 10 days. Examples of oxidative stress mediated neurodegenerative disorders that can be treated in this way include amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), cerebral amyloid angiopathy (CAA), Alzheimer's disease and Parkinson's disease.

EA202090221A 2018-02-20 2018-07-06 USE OF EDARAVON FOR ORAL TREATMENT OF MEDIATED OXIDATIVE STRESS OF NEURODEGENERATIVE DISORDERS EA202090221A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18157678 2018-02-20
PCT/EP2018/068396 WO2019008144A1 (en) 2017-07-06 2018-07-06 Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders

Publications (1)

Publication Number Publication Date
EA202090221A1 true EA202090221A1 (en) 2020-04-24

Family

ID=61256595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090221A EA202090221A1 (en) 2018-02-20 2018-07-06 USE OF EDARAVON FOR ORAL TREATMENT OF MEDIATED OXIDATIVE STRESS OF NEURODEGENERATIVE DISORDERS

Country Status (1)

Country Link
EA (1) EA202090221A1 (en)

Similar Documents

Publication Publication Date Title
MX2016014634A (en) Compounds for treating ophthalmic diseases and disorders.
EA201590655A8 (en) COMBINATION OF LACHINIMODE AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
MX2023001299A (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF.
MX2019010994A (en) Methods for treating complement-mediated diseases and disorders.
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
MX2014002459A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
EA201590654A1 (en) COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON'S DISEASE
MX2011007854A (en) Methods for treating acute myocardial infarctions and associated disorders.
MX2014002460A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
EA201490163A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
MA43828A (en) THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
MX2018006247A (en) Methods for treating alzheimer's disease and related disorders.
RU2014150942A (en) TREATMENT OF SIDE EFFECTS IN THE FORM OF MOTOR AND MOTOR DISORDERS RELATED TO THE TREATMENT OF PARKINSON'S DISEASE
MA51056A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
CL2019003903A1 (en) Use of edaravone in the oral treatment of neurodegenerative disorders measured by oxidative stress.
MX2019006141A (en) Methods of treating inflammatory disorders with multivalent fc compounds.
MX2021011269A (en) Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine.
MX2021002017A (en) Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection.
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
EA202090221A1 (en) USE OF EDARAVON FOR ORAL TREATMENT OF MEDIATED OXIDATIVE STRESS OF NEURODEGENERATIVE DISORDERS
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
MA39448A1 (en) (R) -pirlindole and its pharmaceutically acceptable salts for medical use
MX2023010625A (en) Anti-amyloid beta antibodies and uses thereof.